The Rapid Heme Panel was developed by cancer specialists at Dana-Farber Cancer Institute and at Brigham and Women’s Hospital. Jon Aster, MD, PhD discusses the new DNA-based test which relies on relatively new technology that analyzes the 95 genes which are among the most commonly mutated genes in blood cancers such as acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms.